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To evaluate the feasibility of amrubicin plus cisplatin (AP) following chemoradio-
therapy for limited-disease small-cell lung cancer, chemo-na€ıve patients aged
20–70 years with a performance status of 0 or 1 and normal organ functions were
treated with etoposide 100 mg ⁄ m2 on days 1–3, cisplatin 80 mg ⁄m2 on day 1 and
concurrent thoracic radiotherapy at 45 Gy ⁄ 30 fractions (EP-TRT), followed by three
cycles of amrubicin 40 mg ⁄ m2 on days 1–3 and cisplatin 60 mg ⁄m2 on day 1 every
3 weeks. The EP-TRT could be completed in 21 patients (15 male and 6 female
patients with a median age of 62 years). Of these, 2, 1 and 18 (86%) patients
received one, two and three cycles of AP, respectively. Sixteen (76%) patients
required granulocyte-colony stimulating factor (G-CSF) support. Grade 3 ⁄ 4 neu-
tropenia occurred in all patients. Grade 3 febrile neutropenia was observed in
9 patients, lasting for 1 day in 5 patients. The incidences of grade 3 ⁄ 4 thrombocy-
topenia and anemia were 43 and 24%, respectively. Grade 3 infection and anorexia
occurred in 2 and 3 patients, respectively. The response rate was 95%. The median
(95% confidence interval [CI]) progression-free survival (PFS) was 41.9 (0–102)
months, and the 5-year PFS rate (CI) was 41.9% (20.4–63.4%). The median overall
survival (OS) has not been reached yet, and the 5-year OS rate (CI) was 57.8%
(35.2–80.4%). In conclusion, EP-TRT followed by AP therapy was well-tolerated,
although a large number of patients required G-CSF support.
S mall-cell lung cancer (SCLC), which accounts for approxi-mately 13% of all malignant pulmonary tumours, is an
aggressive malignancy with a propensity for rapid growth and
early widespread metastases. Limited disease (LD), defined as
disease confined to one hemithorax, can be encompassed by a
single radiation therapy port, and accounts for roughly 30 to
40% of all cases of SCLC at presentation.(1) LD-SCLC has
been treated with chemotherapy and thoracic radiotherapy
(TRT). A phase III trial of concurrent versus sequential twice-
daily TRT (45 Gy ⁄30 fractions over 3 weeks) in combination
with four cycles of etoposide plus cisplatin (EP) therapy in
patients with LD-SCLC (JCOG 9104) showed that the concur-
rent treatment yielded better outcomes than the sequential
treatment, with a median survival time of 27 months and
5-year survival rate of 24%.(2) Another phase III trial compar-
ing single-daily TRT (45 Gy ⁄25 fractions over 5 weeks) ver-
sus twice-daily TRT (45 Gy ⁄30 fractions over 3 weeks)
concurrently with four cycles of EP therapy in patients with
LD-SCLC resulted in survival benefit in the twice-daily TRT
group; the median survival time was 23 months and the 5-year
survival rate was 23%.(3) In addition, prophylactic cranial radi-
ation (PCI) in patients showing complete response (CR) during
the induction treatment has been shown to decrease the cumu-
lative incidence of brain metastasis by half and to improve the
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3-year survival rate by 5.4%.(4) Thus, four cycles of EP ther-
apy and twice-daily TRT beginning with cycle 1 of
chemotherapy followed by PCI is regarded as the standard
treatment for patients with LD-SCLC.
Although LD-SCLC is initially highly responsive to both
chemotherapy and radiotherapy, the majority of patients ulti-
mately relapse and die of the disease. The effects of the addition
of a third agent to EP therapy and an increase in the total dose of
TRT have been investigated to enhance the therapeutic effect.
These attempts, however, have produced substantial toxicity and
have failed to improve survival.(1) In contrast, we have made
modifications to the chemotherapy regimen following the induc-
tion standard chemoradiotherapy. Two phase II trials of three
cycles of cisplatin plus irinotecan after EP therapy and twice-
daily TRT in patients with LD-SCLC showed promising 3-year
survival rates of 30–38%,(5,6) although this regimen failed to
show superiority to the standard regimen in a phase III trial.(7)
Amrubicin, a totally synthetic 9-amino-anthracycline and
potent topoisomerase II inhibitor, has been developed for the
treatment of SCLC. A phase II trial of amrubicin monotherapy
in chemo-na€ıve patients with extensive SCLC showed an objec-
tive response rate (ORR) of 76% and median overall survival
(OS) of 11.8 months, comparable to the results obtained with
EP therapy.(8) When combined with cisplatin, amrubicin showed
promising antitumor effects against extensive disease (ED)-
SCLC in a phase II trial with an ORR of 88% and a median OS
of 13.6 months.(9) In addition, providing a chemotherapy regi-
men in the consolidation phase different from that in the induc-
tion phase may be important to suppress the emergence of
chemo-resistant clones in tumors. Thus, the introduction of cis-
platin plus amrubicin chemotherapy (AP therapy) for treatment
of LD-SCLC may be worthwhile, although a recent phase III
trial in patients with ED-SCLC failed to show superiority of AP
therapy to a combination of irinotecan and cisplatin.(10)
The objectives of the present study were to evaluate the tox-
icity and feasibility of AP therapy following EP therapy plus
twice-daily TRT, and to observe the antitumor effects of this
regimen in patients with LD-SCLC.
Patients and Methods
Study design. This study was designed as a multi-institu-
tional feasibility study. The protocol and consent form were
approved by the Institutional Review Board of each institution.
The primary endpoint was the treatment completion rate
(TCR), and the secondary endpoints were toxicity, ORR, pro-
gression-free survival (PFS) and OS.
Patient selection. The eligibility criteria were: (1) histologi-
cally or cytologically proven SCLC; (2) LD (confined to one
hemithorax, but excluding contralateral hilar lymph node
involvement); (3) age between 20 and 70 years; (4) Eastern
Cooperative Oncology Group performance status (PS) of 0 or
1; (5) measurable disease; (6) percent volume of the normal
lung receiving 20 Gy or more (V20) ≤ 35%, and indication for
curative thoracic radiotherapy determined by a radiation oncol-
ogist; (7) no previous treatment for SCLC; (8) no previous
chemotherapy for other tumors, except for oral chemotherapy
as adjuvant chemotherapy after surgery; (9) adequate bone
marrow function (white blood cell [WBC] count
≥4.0 9 109 ⁄L, hemoglobin ≥9.0 g ⁄dL, and platelet count
≥100 9 109 ⁄L), liver function (total bilirubin ≤1.5 mg ⁄dL and
transaminase ≤2.5 times the upper limit of the normal range),
renal function (serum creatinine ≤1.25 times the upper limit of
the normal range) and pulmonary function (PaO2 ≥70 Torr
under room air); and (10) availability of written informed con-
sent. Patients were excluded if they had: (1) malignant pleural
or pericardial effusion, with the exception of small effusions
(1 cm or less) seen only on chest computed tomography (CT)
scan; (2) active prior malignancies with a disease-free interval
of <5 years, except for carcinoma in situ cured by local ther-
apy; or (3) concomitant serious illness such as uncontrolled
angina pectoris, myocardial infarction in the previous
6 months, uncontrolled arrhythmia, uncontrolled diabetes mel-
litus, uncontrolled hypertension, interstitial pneumonitis or
lung fibrosis identified on chest x-ray, infection, mental disor-
der or other diseases representing contraindications for
chemotherapy or radiotherapy, and any diseases requiring sys-
temic steroid administration. Pregnant or lactating women were
ineligible.
Pretreatment evaluation. The pretreatment assessment
included a complete blood count, routine chemistry determina-
tions, measurement of the creatinine clearance, blood gas anal-
ysis, electrocardiography, lung function testing, chest x-ray
examination, chest CT, brain CT or magnetic resonance imag-
ing, abdominal CT, and radionuclide bone scintigraphy or
positron emission tomography.
Treatment schedule. Induction EP therapy consisted of one
cycle of cisplatin 80 mg ⁄m2 on day 1 and etoposide 100 mg
⁄m2 on days 1 to 3. Cisplatin was administered by i.v. infusion
over 60 to 120 min with 2500 to 3000 mL of i.v. hydration
fluids and standard prophylactic antiemetic therapy consisting
of a 5-hydroxytryptamine-3 receptor antagonist and a steroid.
On day 2 of the EP therapy, TRT was begun and delivered
from a megavoltage equipment (6–10 MV) at a fraction dose of
1.5 Gy twice daily, with at least a 6-h interval between the frac-
tions, to a total dose of 45 Gy administered in 30 fractions over
3 weeks. All patients underwent a 3-D treatment-planning CT 3
to 7 days before the start of the treatment. The gross tumor vol-
ume (GTV) was defined as the primary tumor delineated on pul-
monary windows of the chest CT. Atelectasis or secondary
changes in the peripheral lung region of the primary tumor were
not included. Metastatic lymph nodes were defined as nodes
1 cm or larger in the short axis diameter visualized on mediasti-
nal windows of the CT images. The clinical target volume
(CTV) included the GTV (CTVprimary and CTVnode) and
uninvolved regional lymph nodes, including ipsilateral hilar and
bilateral mediastinal (#2, 3, 4, 7) lymph nodes (CTVsubclinical).
The other regions were not routinely included unless metastatic
nodes were noted. The contralateral hilar lymph node was
excluded from the CTV. The planning target volume (PTV) was
determined as the CTV plus 1.0 cm for the anterior, posterior,
medial and lateral margins, and 1.0 to 2.0 cm for the superior
and inferior margins, taking into account setup variations and
internal organ motions. A total of 30 Gy was delivered to the
PTVprimary, PTVnode and PTVsubclinical, and a boost radia-
tion dose of 15 Gy was delivered to the PTVprimary and
PTVnode only. Lung heterogeneity corrections were not applied.
The spinal cord dose was limited to 36 Gy.
Following chemoradiotherapy, the patients were assessed to
determine their fulfillment of the following criteria for the start
of AP therapy: PS of 0–1, WBC count ≥3.0 9 109 ⁄L, platelet
count ≥100 9 109 ⁄L, serum hepatic transaminase levels
≤2.5 times the upper limit of the normal range, total serum
bilirubin level ≤ 1.5 mg ⁄dL, serum creatinine ≤1.5 mg ⁄dL,
fever <37.5°C, and no active infection. Stable radiation pneu-
monitis was allowed if all of the following criteria were met:
(1) no aggravation of symptoms, including cough, fever or
dyspnea; (2) PaO2 ≥ 70 Torr or SpO2 ≥ 93%; (3) no infiltrates
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or consolidation over the irradiated area on a chest X-ray; and
(4) no requirement of oxygen or steroid therapy.
Amrubicin 40 mg ⁄m2 on days 1 to 3 and cisplatin 60 mg ⁄m2
on day 1 were started on day 29 of the induction chemotherapy,
and repeated every 3 to 4 weeks for three cycles. After the AP
therapy, PCI at a total dose of 25 Gy in 10 fractions was added
for patients showing CR or near CR, defined as a reduction by
>70% of the sum of the greatest dimensions of the lesions.
Toxicity assessment and treatment modification. Complete
blood counts, routine chemistry determinations, and a chest x-
ray were performed at least once a week during the course of
treatment. Toxicity was graded according to the Common Ter-
minology Criteria for Adverse Events (CTCAE) version 3.0.
The lung toxicity grade was defined as the highest grade
among those for cough, dyspnea, airway obsturction, pneu-
monitis ⁄pulmonary infiltrates and pulmonary fibrosis in the
pulmonary ⁄upper respiratory section of the CTCAE version
3.0.(11)
Subsequent cycles of AP therapy were delayed if any of the
following toxicities were noted on day 1: WBC count
<3.0 9 109 ⁄L, platelet count <100 9 109 ⁄L, serum hepatic
transaminase levels >2.5 times the upper limit of the normal
range, total serum bilirubin level >1.5 mg ⁄ dL, fever ≥37.5°C,
active infection, unstable pneumonitis or PS of 2‒3. If these
toxicities did not recover within 6 weeks from day 1 of the
previous cycle of AP therapy, subsequent cycles were not
administered. If the serum creatinine level was 1.6‒2.0 mg ⁄ dL
on day 1, the dose of cisplatin was reduced to 45 mg ⁄m2, and
if it was above 2.0 mg ⁄dL, cisplatin administration was omit-
ted. If grade 3 febrile neutropenia was noted, prophylactic
granulocyte-colony stimulating factor (G-CSF) support was
started on day 5 of the subsequent cycles. If grade 3 febrile
neutropenia was noted again despite the prophylactic G-CSF
support, then the dose of amrubicin was reduced by 10 mg ⁄m2
in subsequent cycles. If grade 4 thrombocytopenia or grade 3
non-hematological toxicity other than nausea, vomiting and
transient electrolyte disturbances was noted, the dose of amru-
bicin was reduced by 10 mg ⁄m2 in subsequent cycles. Any
protocol-defined treatments were terminated if grade 4 non-
hematological toxicities other than transient electrolyte distur-
bances or a PS of 4 was noted.
Response evaluation. Objective tumor response was evalu-
ated according to the Response Evaluation Criteria in Solid
Tumors (RECIST), version 1.0.(12)
Statistical analyses. The primary objective of this study was
to evaluate the feasibility of a new combination chemotherapy
following induction chemoradiotherapy. However, the criteria
of feasibility in this setting have not yet been established.
Thus, we arbitrarily defined treatment completion (TC) as
completion of two to three cycles of AP therapy without
grade 4 non-hematological toxicity or treatment-related death,
and the TCR, the primary endpoint of this study, as the per-
centage of patients achieving TC relative to the total number
of patients. In conformity with phase I trials of investigational
new agents, if four to six of the initial six patients met the cri-
teria of TC, then 6–15 patients were added to confirm that the
TC rate would be two-thirds or higher. We did not calculate
the sample size to ensure the alpha-error or beta-error of the
TC rate.
The PFS and OS were estimated using the Kaplan–Meier
method. They were measured from the date of registration to
the occurrence of an event, defined as the date of detection of
disease progression, date of death from any cause, or date of
the last follow-up for evaluation of the PFS, and the date of
death from any cause or that of the last follow-up for evalua-
tion of the OS. Patients who were lost to follow-up without
events were censored at the last known date of follow-up. A
confidence interval (CI) for the response rate was calculated
by the method used for exact binomial CI. The STATA statis-
tical software, version 11 (StataCorp LP, TX USA), was used
for the statistical analyses.
Results
From August 2007 to June 2009, 21 patients were enrolled in
this study, and their characteristics are summarized in Table 1.
There were 15 male patients and 6 female patients, with a
median age of 62 years (range, 46‒70 years). All the patients
had LD-SCLC and were in good general condition.
Of the 21 patients, EP therapy was completed without dose
modification in 20 patients, and 1 patient received cisplatin on
day 1 and etoposide on days 2‒3, but etoposide on day 3 had
to be omitted because of the development of grade 3 diarrhea.
TRT was completed at the full dose in all patients. The toxic-
ity of EP therapy administered concurrently with TRT was
mainly hematological. Grade 3‒4 neutropenia and grade 3 feb-
rile neutropenia were noted in 91 and 29% of the patients,
respectively, but they were manageable in all cases (Table 2).
With a median (range) interval between the EP and AP ther-
apies of 28 (28–43) days, AP therapy was started in all
patients. Three cycles of AP therapy were administered in 18
patients, two cycles in 1 patient, and one cycle in 2 patients.
Thus, the TC rate was 90.5% (19 ⁄21). The reasons for admin-
istration of no more than one to two cycles of AP therapy only
in 3 patients were severe toxicity, delay in recovery from toxi-
city, and patient refusal in 1 patient each. The median (range)
interval between the first and second cycles of AP therapy in
19 patients was 28 (21–36) days, and that between the second
and third cycles of AP therapy in 18 patients was 27.5 (21–35)
days. A reduction in the amrubicin dose in subsequent cycles
was necessitated in 7 (33%) patients. G-CSF support was used
in 16 (76%) patients, whereas transfusion of red blood cells
and platelets was required in 3 (14%) patients each.
Grade 3–4 leukopenia and neutropenia were noted in all
patients. Grade 3 febrile neutropenia was noted in 9 (43%)
patients, but the duration of fever ≥38°C was only 1 day in
5 patients, 3 days in 1 patient, and 5 to 7 days in three
Table 1. Patient characteristics
Characteristics N %
Sex
Male 15 71
Female 6 29
Age
Median (range) 62 46–70
Performance status
0 17 81
1 4 19
Body weight loss (%)
0 17 81
0.1–4.9 2 10
5.0 2 10
V20* (%)
Median (range) 19 10–34
*V20: The percent volume of the normal lung receiving 20 Gy or
more.
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patients. All of these patients recovered, and no treatment-
related deaths were noted (Table 3).
Seventeen (81%) patients received PCI. The reasons for not
administering PCI were persistent toxicity of previous AP ther-
apy in 1 patient, not achieving CR or near CR in 2 patients,
and patient refusal in 1 patient.
The tumor response was not assessable in 1 patient because
she refused to receive subsequent therapy after one cycle of
AP therapy. Among the remaining 20 patients, 2 CR and 18
partial responses were observed, and, therefore, the ORR in
the 21 patients was 95% (95% CI, 76.2–99.9%). The median
progression-free survival (PFS) was 41.9 months (95% CI,
0–102 months), and the 3-year and 5-year PFS rates were
52.4% (95% CI, 31.0–73.8%) and 41.9% (95% CI, 20.4–
63.4%), respectively (Fig. 1). The median overall survival
(OS) has not been reached yet, and the 3-year and 5-year OS
rates were 63.6% (95% CI, 41.8–85.4%) and 57.8% (95% CI,
35.2–80.4%), respectively (Fig. 2).
Discussion
The TC rate, the primary endpoint of this study, was 90.5%,
which exceeded the protocol-defined criteria of feasibility of
67%. In addition, full cycles of AP therapy were delivered in
18 (86%) patients. These results suggest that administration of
three cycles of AP therapy following EP therapy and TRT is
feasible in patients with LD-SCLC.
The dose of amrubicin needed to be reduced in 33% (7 of
21) of the patients. This figure is comparable to that in a previ-
ous phase I ⁄ II study of AP therapy for previously untreated
extensive SCLC, where dose escalation was determined based
on the data from the first course of chemotherapy. In this
study, the dose of amrubicin was reduced in 17% of patients
Table 2. Toxicity of induction chemoradiotherapy
Grade 1 2 3 4 3 + 4 %
Leukopenia 0 1 12 8 20 95
Neutropenia 0 2 6 13 19 91
Anemia 16 0 0
Thrombocytopenia 12 4 0 0
Febrile neutropenia 0 0 6 6 29
AST elevation 2 0 0
ALT elevation 4 1 0 0
Hyperbilirubinemia 3 2 0 0
Creatinine elevation 3 0 0
Hyponatremia 7 0 2 2 10
Hyperkalemia 4 0 0
Allergic reaction 1 1 0 0
Anorexia 9 5 2 2 10
Nausea 7 10 0 0
Vomiting 5 2 0 0
Mucositis 2 0 0
Diarrhea 1 0 1 1 5
Constipation 4 1 0 0
Esophagitis 8 12 0 0
Dermatitis associated with radiation 8 0 0
Table 3. Toxicity of cisplatin plus amrubicin chemotherapy
Grade 1 2 3 4 3 + 4 %
Leukopenia 0 0 7 14 21 100
Neutropenia 0 0 4 17 21 100
Anemia 3 13 4 1 5 24
Thrombocytopenia 4 6 6 3 9 43
Febrile neutropenia 0 0 9 9 43
AST elevation 4 0 0
ALT elevation 3 0 0
Hyperbilirubinemia 3 1 0 0
Creatinine elevation 6 0 0
Hyponatremia 9 0 1 1 5
Hyperkalemia 5 0 1 1 5
Infection 0 0 2 2 10
Allergic reaction 1 0 0
Anorexia 7 7 3 3 14
Nausea 8 6 0 0
Vomiting 1 3 0 0
Mucositis 1 3 0 0
Diarrhea 3 0 1 1 5
Constipation 6 2 1 1 5
Esophagitis 6 7 1 1 5
Pneumonitis 4 3 0 0
Dermatitis associated with radiation 4 1 0 0
Fig. 1. Progression-free survival (n = 21).
Fig. 2. Overall survival (n = 21).
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in the second cycle, 21% of patients in the third cycle, and
31% of patients in the fourth cycle.(9) Unlike in the previous
study, however, this study targeted patients with LD-SCLC,
which is potentially curative as long as sufficient chemother-
apy has been administered. Thus, the initial dose of
chemotherapy should not be reduced too quickly in patients
with LD-SCLC.
The interval between cycles of AP therapy was set at 3 to
4 weeks in the protocol, and the current results showed that
the actual median interval was 28 days. It is well known that
recovery of myelosuppression is delayed when TRT is added
to systemic chemotherapy. In the JCOG phase III study com-
paring concurrent and sequential TRT combined with four
cycles of EP therapy, the interval between cycles of the EP
therapy was 4 weeks in the concurrent treatment group and
3 weeks in the sequential treatment group, and the actual
hematological toxicity was more severe in the former treat-
ment group.(2) Thus, the interval between cycles of AP therapy
of 28 days in this study is considered to be acceptable in con-
current chemoradiotherapy.,
Myelotoxicity, the primary toxicity in this study, was severe,
as suggested by grade 3–4 neutropenia developing in all
patients and grade 3 febrile neutropenia developing in 9 (43%)
patients. More than half of these patients, however, recovered
within 1 day, and there were no treatment-related deaths. G-
CSF support was used in 16 (76%) patients, suggesting that
prophylactic G-CSF support will be helpful for subsequent
studies.
Limitations of this study included the number of patients,
which was insufficient for obtaining statistical power, and the
fact that it was conducted in five high-volume cancer centers
in Japan. Thus, the feasibility of this regimen as well as its
antitumor activity against LD-SCLC should be confirmed in a
phase II study conducted with the participation of many city
hospitals, followed by a large phase III study.
Although evaluation of the antitumor activity in this study
was limited by the small number of patients, the results were
impressive. The 5-year PFS rate was 41.9% (95% CI, 20.4–
63.4%), and the 5-year OS rate was 57.8% (95% CI, 35.2–
80.4%). With the encouraging results, we are conducting a ran-
domized phase II trial of the AP therapy or weekly combina-
tion chemotherapy (CODE regimen) following the EP ⁄TRT
therapy in patients with chemo-na€ıve LD-SCLC (JCOG1011).
In conclusion, EP-TRT followed by three cycles of AP was
well-tolerated, although most patients required G-CSF support.
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